Perrigo Company plc reiterated earnings guidance for the fiscal year 2022. For the fiscal year, the company reiterated fiscal 2022 organic net sales growth range outlook of 9.0% - 10.0% and total net sales growth range of 8.5% - 9.5% as expected accretion from the Gateway plant, along with the U.S. and Canadian rights to the Good Start infant formula brand, are expected to offset the worsening impact of currency translation. If foreign currency exchange rates hold near current levels, the company now expect net sales in the full year to be unfavorably impacted by 5%-6%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.08 USD | -0.46% | +3.96% | -2.95% |
Apr. 08 | Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating | MT |
Apr. 04 | CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.95% | 4.23B | |
+23.02% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.26% | 219B | |
+6.39% | 199B | |
-10.06% | 196B | |
-8.75% | 149B | |
-5.21% | 146B |
- Stock Market
- Equities
- PRGO Stock
- News Perrigo Company plc
- Perrigo Company plc Reiterates Earnings Guidance for the Fiscal Year 2022